腦膜炎雙球菌疫苗市場規模、佔有率和成長分析（按疫苗類型、品牌、年齡層、最終用戶和地區）：產業預測（2024-2031）

2022年全球腦膜炎雙球菌疫苗市場規模估值為43億美元，從2023年的45.8億美元成長到2031年的75.8億美元，預計在預測期內（2024-2031年）將成長。成長率為6.5%。

根據 CDC 報告，在腦膜炎發病率上升的推動下，腦膜炎雙球菌疫苗市場預計將出現顯著成長，全球整體估計有 120 萬例腦膜炎病例。強化免疫舉措、提高公眾意識以及活性化圍繞腦膜炎球菌疫苗的研發活動預計將進一步推動市場擴張。由國家腦膜炎協會和腦膜炎研究基金會等組織主導的許多宣傳活動正在提高人們的意識並推廣創新的預防策略。市面上有許多針對腦膜炎奈瑟菌的疫苗，包括針對 A、B、C、W-135 和 Y 菌株的單價和多效價疫苗。此外，儘管嚴格的監管措施帶來的潛在挑戰是主要影響因素，但這些疫苗擴大融入國家免疫計劃以及旅行疫苗供應的不斷擴大也推動了市場動態。

目錄

介紹

• 分析目的
• 市場範圍
• 定義

分析方法

• 資訊採購
• 次要/主要資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 市場概況及展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及前景

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特分析及影響
  • 競爭公司之間的敵對關係
  • 替代品的威脅
  • 買方議價能力
  • 新進入者的威脅
  • 供應商的議價能力

主要市場考慮因素

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場魅力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術進步
• 監管環境
• 案例研究
• 客戶和購買標準分析

全球腦膜炎雙球菌疫苗市場規模和複合年成長率：按疫苗類型分類（2024-2031）

• 市場概況
• 多醣體疫苗
• 結合疫苗
  • 四價
  • 二價
  • 單價
• 聯合疫苗
• B 型腦膜炎雙球菌 (Men-B) 疫苗

全球腦膜炎雙球菌疫苗市場規模和複合年成長率：按品牌分類（2024-2031）

• 市場概況
• 梅納克特拉
• 門貝奧
• 尼門里克斯
• 貝克塞洛
• 托門巴
• 其他

全球腦膜炎雙球菌疫苗市場規模和複合年成長率：按年齡層分類（2024-2031）

• 市場概況
• 嬰兒
• 孩子們
• 青年
• 成人

全球腦膜炎雙球菌疫苗市場規模和複合年成長率：按最終用戶分類（2024-2031）

• 市場概況
• 醫院
• 診所
• 疫苗接種中心
• 其他

全球腦膜炎雙球菌疫苗市場規模及複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要企業採取的策略
• 近期市場趨勢
• 主要企業市場佔有率（2023年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi SA
• Merck & Co., Inc.
• Novartis AG
• CSL Limited
• Serum Institute of India Pvt. Ltd.
• Biomed Pvt. Ltd.
• Bharat Biotech
• Biological E. Limited
• Hualan Biological Engineering Inc.
• Walvax Biotechnology Co., Ltd.
• Chongqing Zhifei Biological Products Co., Ltd.
• Emergent BioSolutions Inc.
• Incepta Vaccine Ltd.
• Panacea Biotec Ltd.
• LG Chem Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Valneva SE
• Vaxart, Inc.

結論和建議

Global Meningococcal Vaccines Market size was valued at USD 4.30 billion in 2022 and is poised to grow from USD 4.58 billion in 2023 to USD 7.58 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2024-2031).

The meningococcal vaccines market is poised for significant growth, driven by the rising incidence of meningitis, with an estimated 1.2 million cases globally, as reported by the CDC. Enhanced immunization initiatives, heightened public awareness, and intensified research and development activities surrounding meningococcal vaccines are expected to further bolster market expansion. Numerous campaigns led by organizations like the National Meningitis Association and the Meningitis Research Foundation are raising awareness and promoting innovative prevention strategies. The market features various vaccines targeting Neisseria meningitidis, including monovalent and multivalent options against strains A, B, C, W-135, and Y. Additionally, the increasing integration of these vaccines into national immunization programs and the growth of travel vaccination availability are key factors influencing market dynamics, despite potential challenges from strict regulatory measures.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Meningococcal Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Meningococcal Vaccines Market Segmental Analysis

Global Meningococcal Vaccines Market is segmented by vaccine type, brand, age group, end user and region. Based on vaccine type, the market is segmented into polysaccharide vaccines, conjugate vaccines (quadrivalent, bivalent, monovalent), combination vaccines and men b vaccines. Based on brand, the market is segmented into menactra, menveo, nimenrix, bexsero, trumenba and others. Based on age group, the market is segmented into infants, children, adolescents and adults. Based on end user, the market is segmented into hospitals, clinics, vaccination centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Meningococcal Vaccines Market

A significant factor propelling the global meningococcal vaccines market is the growing incidence of meningococcal diseases worldwide. The emergence of meningitis and septicemia caused by Neisseria meningitidis presents a serious health threat, resulting in high mortality rates and potential long-term consequences, including neurological damage. Consequently, healthcare providers are increasingly focusing on preventive measures, particularly vaccination, to curb these outbreaks. This concern is particularly pronounced in specific regions, such as Sub-Saharan Africa, often referred to as the "meningitis belts," where the prevalence of infections is notably higher, thereby driving the demand for effective vaccines in these vulnerable areas.

Restraints in the Global Meningococcal Vaccines Market

A significant restraint within the global meningococcal vaccines market is the prohibitively high production and distribution costs. The advanced vaccines, particularly those utilizing conjugate and recombinant technologies, are not easily accessible in low-income regions that are disproportionately affected by meningococcal disease. Despite efforts from governmental and non-governmental organizations to provide subsidies, the overall affordability of these vaccines continues to pose a major challenge. This financial barrier ultimately limits the reach of vaccination programs, hindering efforts to achieve broad immunization coverage and protect vulnerable populations from the potentially devastating impacts of meningococcal infections.

Market Trends of the Global Meningococcal Vaccines Market

The global meningococcal vaccines market is witnessing a significant trend towards the adoption of combination vaccines, particularly quadrivalent formulations that provide protection against serogroups A, C, W, and Y. This preference is largely driven by the advantages these vaccines offer, including wider coverage and the convenience of requiring fewer doses. As healthcare systems aim to improve immunization rates and streamline vaccine administration processes, combination vaccines are becoming essential in overcoming logistical hurdles and enhancing patient adherence to vaccination schedules. This trend not only reflects a growing awareness of meningococcal disease but also represents a pivotal shift towards more effective public health strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Meningococcal Vaccines Market Size by Vaccine Type & CAGR (2024-2031)

• Market Overview
• Polysaccharide Vaccines
• Conjugate Vaccines
  • Quadrivalent
  • Bivalent
  • Monovalent
• Combination Vaccines
• Men B Vaccines

Global Meningococcal Vaccines Market Size by Brand & CAGR (2024-2031)

• Market Overview
• Menactra
• Menveo
• Nimenrix
• Bexsero
• Trumenba
• Others

Global Meningococcal Vaccines Market Size by Age Group & CAGR (2024-2031)

• Market Overview
• Infants
• Children
• Adolescents
• Adults

Global Meningococcal Vaccines Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Vaccination Centers
• Others

Global Meningococcal Vaccines Market Size & CAGR (2024-2031)

• North America (Vaccine Type, Brand, Age Group, End User)
  • US
  • Canada
• Europe (Vaccine Type, Brand, Age Group, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Vaccine Type, Brand, Age Group, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Vaccine Type, Brand, Age Group, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Brand, Age Group, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomed Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E. Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Walvax Biotechnology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chongqing Zhifei Biological Products Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incepta Vaccine Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panacea Biotec Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation